MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate, sonelokimab (SLK), leading to significant financial losses after disappointing trial results were announced [8]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that MoonLake misrepresented SLK as superior to competing monoclonal antibodies while failing to disclose that it targeted the same molecules as UCB's BIMZELX and had no proven superiority [8]. - Following the announcement of Phase 3 results on September 28, 2025, which showed SLK did not match BIMZELX's efficacy, MoonLake's stock price dropped nearly 90%, resulting in substantial losses for investors [8]. - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, are eligible to apply to be lead plaintiffs in the lawsuit by December 15, 2025 [8]. Group 2: Company Background - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX, focusing on developing innovative therapies [8]. - The firm has faced scrutiny due to the performance of its sole drug candidate, which has been criticized for not delivering on its promised clinical advantages [8].